4beta-Hydroxycholesterol is a lipid of Sterol Lipids (ST) class. 4beta-hydroxycholesterol is associated with abnormalities such as Kidney Failure, Kidney Failure, Chronic, Respiratory Tract Infections, Immunologic Deficiency Syndromes and Infection. The involved functions are known as Selection, Genetic, Renal function, Anabolism, Inflammation and Cell division phases. 4beta-hydroxycholesterol often locates in Hepatic, Blood, Skin and Microsomes. The associated genes with 4beta-Hydroxycholesterol are CYP3A5 gene, Alleles, TERT gene, CYP3A4 gene and CYP3A7 gene. The related lipids are 4-hydroxycholesterol, Hydroxycholesterols, Promega, Pregnanes and 24-hydroxycholesterol.

Cross Reference


To understand associated biological information of 4beta-Hydroxycholesterol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 4beta-Hydroxycholesterol?

4beta-Hydroxycholesterol is suspected in Kidney Failure, Chronic, Kidney Failure, Respiratory Tract Infections, Immunologic Deficiency Syndromes, Infection, Epilepsy and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

No disease MeSH terms mapped to the current reference collection.

PubChem Associated disorders and diseases

What pathways are associated with 4beta-Hydroxycholesterol

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 4beta-Hydroxycholesterol?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with 4beta-Hydroxycholesterol?

Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 4beta-Hydroxycholesterol?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with 4beta-Hydroxycholesterol?

Related references are published most in these journals:

Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 4beta-Hydroxycholesterol?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with 4beta-Hydroxycholesterol

Download all related citations
Per page 10 20 50 100 | Total 63
Authors Title Published Journal PubMed Link
Mao J et al. Strategy for CYP3A Induction Risk Assessment from Preclinical Signal to Human: a Case Example of a Late-Stage Discovery Compound. 2017 Pharm. Res. pmid:28815392
Gjestad C et al. 4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients. 2017 Br J Clin Pharmacol pmid:28585378
Jiang X et al. An Exposure-Response Modeling Approach to Examine the Relationship Between Potency of CYP3A Inducer and Plasma 4β-Hydroxycholesterol in Healthy Subjects. 2017 Clin Pharmacol Drug Dev pmid:27138546
Wollmann BM et al. 4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State. 2017 Clin Transl Sci pmid:27991741
Hole K et al. Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration. 2017 Eur. J. Clin. Pharmacol. pmid:27975131
Oh J et al. Effects of renal impairment on the pharmacokinetics and pharmacodynamics of a novel dipeptidyl peptidase-4 inhibitor, evogliptin (DA-1229). 2017 Diabetes Obes Metab pmid:27761990
Mao J et al. Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A. 2017 Drug Metab. Rev. pmid:27718639
Størset E et al. The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. 2017 Br J Clin Pharmacol pmid:28146606
Vanhove T et al. Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation. 2017 Br J Clin Pharmacol pmid:28603840
Björkhem-Bergman L et al. Effect of Statin Treatment on Plasma 4β-Hydroxycholesterol Concentrations. 2016 Basic Clin. Pharmacol. Toxicol. pmid:26617265
Gjestad C et al. 4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation? 2016 Br J Clin Pharmacol pmid:26574235
Woolsey SJ et al. Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects. 2016 Basic Clin. Pharmacol. Toxicol. pmid:26399557
Pataj Z et al. Quantification of oxysterols in human plasma and red blood cells by liquid chromatography high-resolution tandem mass spectrometry. 2016 J Chromatogr A pmid:26607314
Hasan M et al. Rapid LC-MS/MS method for the determination of 4-hydroxycholesterol/cholesterol ratio in serum as endogenous biomarker for CYP3A activity in human and foals. 2016 J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. pmid:27565568
Vanhove T et al. Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance. 2016 Br J Clin Pharmacol pmid:27501475
Aubry AF et al. Recommendations on the Development of a Bioanalytical Assay for 4β-Hydroxycholesterol, an Emerging Endogenous Biomarker of CYP3A Activity. 2016 AAPS J pmid:27350147
Ishida T et al. Relationship between the plasma fentanyl and serum 4β-hydroxycholesterol based on CYP3A5 genotype and gender in patients with cancer pain. 2016 Drug Metab. Pharmacokinet. pmid:27236640
Xue YJ et al. Use of 4β-hydroxycholesterol in animal and human plasma samples as a biomarker for CYP3A induction. 2016 Bioanalysis pmid:26805594
Hukkanen J et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. 2015 Br J Clin Pharmacol pmid:26095142
de Graan AJ et al. 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. 2015 Br J Clin Pharmacol pmid:26119961
Mannheimer B et al. No impact of vitamin D on the CYP3A biomarker 4β-hydroxycholesterol in patients with abnormal glucose regulation. 2015 PLoS ONE pmid:25835492
Naito T et al. CYP3A activity based on plasma 4β-hydroxycholesterol during the early postpartum period has an effect on the plasma disposition of amlodipine. 2015 Drug Metab. Pharmacokinet. pmid:26654672
Suzuki Y et al. Association of plasma concentration of 4β-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients. 2014 Drug Metab. Dispos. pmid:24135442
Dutreix C et al. Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin. 2014 Eur. J. Clin. Pharmacol. pmid:24839948
Kasichayanula S et al. Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects. 2014 Br J Clin Pharmacol pmid:24837659
Nylén H et al. Plasma levels of 25-hydroxyvitamin D3 and in vivo markers of cytochrome P450 3A activity in Swedes and Koreans: effects of a genetic polymorphism and oral contraceptives. 2014 Basic Clin. Pharmacol. Toxicol. pmid:24655660
Li K et al. 4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys. 2014 Drug Metab. Dispos. pmid:24595680
Ngaimisi E et al. Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. 2014 J. Antimicrob. Chemother. pmid:25096076
Huang MQ et al. Quantitation of P450 3A4 endogenous biomarker - 4β-hydroxycholesterol - in human plasma using LC/ESI-MS/MS. 2014 Biomed. Chromatogr. pmid:24861746
Ikegami T et al. Increased serum oxysterol concentrations in patients with chronic hepatitis C virus infection. 2014 Biochem. Biophys. Res. Commun. pmid:24525121
Higashi T et al. LC/MS/MS of steroids having vicinal diol as electrospray-active boronates. 2013 Chem. Pharm. Bull. pmid:23449202
Suzuki Y et al. Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation. 2013 J. Lipid Res. pmid:23833241
Nury T et al. Biological activities of the LXRα and β agonist, 4β-hydroxycholesterol, and of its isomer, 4α-hydroxycholesterol, on oligodendrocytes: effects on cell growth and viability, oxidative and inflammatory status. 2013 Biochimie pmid:23220593
Björkhem-Bergman L et al. Serum levels of 25-hydroxyvitamin D and the CYP3A biomarker 4β-hydroxycholesterol in a high-dose vitamin D supplementation study. 2013 Drug Metab. Dispos. pmid:23386704
Shin KH et al. Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. 2013 Clin. Pharmacol. Ther. pmid:23784264
van de Merbel NC and de Vries R Aging of biological matrices and its effect on bioanalytical method performance. 2013 Bioanalysis pmid:24066624
DeGorter MK et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. 2013 Circ Cardiovasc Genet pmid:23876492
Xu Y et al. LC-ESI-MS/MS quantification of 4β-hydroxycholesterol and cholesterol in plasma samples of limited volume. 2013 J Pharm Biomed Anal pmid:23948760
Björkhem-Bergman L et al. Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin. 2013 Drug Metab. Dispos. pmid:23674608
Mårde Arrhén Y et al. A comparison of 4β-hydroxycholesterol : cholesterol and 6β-hydroxycortisol : cortisol as markers of CYP3A4 induction. 2013 Br J Clin Pharmacol pmid:23116409
Goodenough AK et al. Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis. 2011 Chem. Res. Toxicol. pmid:21728364
Peters J et al. Oral absorption of clarithromycin is nearly abolished by chronic comedication of rifampicin in foals. 2011 Drug Metab. Dispos. pmid:21690264
Nylén H et al. Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4β-hydroxycholesterol. 2011 Eur. J. Clin. Pharmacol. pmid:21246351
van de Merbel NC et al. A validated liquid chromatography-tandem mass spectrometry method for the quantitative determination of 4β-hydroxycholesterol in human plasma. 2011 J Pharm Biomed Anal pmid:21507593
Gebeyehu E et al. Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians. 2011 Pharmacogenomics J. pmid:20231858
Diczfalusy U et al. 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. 2011 Br J Clin Pharmacol pmid:21219398
Yang Z and Rodrigues AD Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric? 2010 J Clin Pharmacol pmid:20197489
Lütjohann D et al. 4beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo - effects of itraconazole in man. 2009 Int J Clin Pharmacol Ther pmid:19954708
Tomalik-Scharte D et al. Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric? 2009 Clin. Pharmacol. Ther. pmid:19458613
Honda A et al. Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS. 2009 J. Lipid Res. pmid:18815436